Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain-Containing Proteins.

Authors

Cole R Scholtz, William C K Pomerantz

Published in

Chembiochem : a European journal of chemical biology. Volume 27. Issue 13. Pages e70443. Jul 14, 2026.

Abstract

Bromodomain-containing proteins serve as epigenetic regulators, where bromodomains recognize acetylated proteins and histones to drive changes in gene expression. Due to their regulatory role in gene expression, bromodomain-containing proteins have served as important targets for drug-discovery efforts, in particular the bromodomain and extra-terminal (BET) family proteins. The selective targeting of these proteins through both inhibition and targeted protein degradation has revealed diverse biological mechanisms. For BET bromodomain-containing proteins, we discuss the unique biological effects of selective inhibition and degradation for efficacy and clinical safety concerns for both BET inhibitors that have entered Phase III clinical trials and recent BET degrader clinical candidates. We also describe the current inhibitory and targeted protein degradation approaches of non-BET bromodomain-containing proteins. This review summarizes current approaches of bromodomain-targeting inhibition and degradation to provide insight on molecular mechanisms and updates the clinical progress of these modalities as the field awaits the approval of the first bromodomain-targeted therapeutic.

PMID:
42376709
Bibliographic data and abstract were imported from PubMed on 30 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.